TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
about
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate CancerTargeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI InhibitorsHedgehog Cholesterolysis: Specialized Gatekeeper to Oncogenic SignalingClinical Implications of Hedgehog Pathway Signaling in Prostate CancerThe Role of Hedgehog Signaling in Tumor Induced Bone DiseaseGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsParacrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironmentNovel non-AR therapeutic targets in castrate resistant prostate cancerHedgehog signaling in prostate epithelial-mesenchymal growth regulation.Hedgehog signaling in prostate cancer and its therapeutic implicationStromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer.Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies.SHH inhibitors for the treatment of medulloblastoma.Oral simvastatin administration delays castration-resistant progression and reduces intratumoral steroidogenesis of LNCaP prostate cancer xenografts.Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.The Hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells.Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.Patched 1 Expression Correlates with Biochemical Relapse in High-Risk Prostate Cancer Patients.Design and Evolution of a Macrocyclic Peptide Inhibitor of the Sonic Hedgehog/Patched Interaction.
P2860
Q26742062-A1E48529-E39D-4067-A373-27845B771A21Q26764892-B4A67237-22A4-4FEA-B80D-DBFC12E07025Q26782305-620223BD-4B33-40CD-825E-00A7AB24BA29Q26783028-3B6B3117-7F13-42E3-9576-F9AB53CFD66CQ26783615-06EBAA2E-21E2-4389-A39B-EC1C1F2FC5F3Q26827975-A8EAB83B-6856-4ACA-98FA-AEB93797C6BDQ28278828-D92C79F6-85B7-4A6F-A60A-F130B0642493Q28383663-5F1436A6-8723-468B-87E5-AAE2AF9CD49AQ35181159-517EF544-4293-4107-86B5-213ABEFD1A5DQ37091887-124BB622-0DEC-4B37-A12F-03604B456B88Q37612667-241E4BD6-9BE2-44F4-BCB2-3C16DF47AD5DQ38213666-601DFCC1-0A48-4329-A804-9324378F4B11Q38509205-34ABD6A5-3A38-4D0A-8316-FC6D32E7965FQ38846889-CFB23854-D964-4DF9-ABE7-FBDCBEB9EAF0Q39202889-610ACCD2-C297-4C71-BB6A-35D42CBCD1CAQ41865304-A1620073-B336-44AD-AF82-6F9FA79F39DAQ47107021-A3855DC6-ABA0-48CE-8234-BFD6EBCD730BQ47562519-B3523A76-2E60-494F-959D-4734A6A980AAQ48009081-2BB837E5-465C-4EF9-83EA-E38C5B1B0DF6
P2860
TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@en
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@nl
type
label
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@en
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@nl
prefLabel
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@en
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@nl
P2093
P2860
P356
P1476
TAK-441, a novel investigation ...... paracrine hedgehog signaling.
@en
P2093
Hideaki Tojo
Ladan Fazli
Martin E Gleave
Masahide Kashiwagi
Mazyar Ghaffari
Michael E Cox
Mitali Pandey
Naokazu Ibuki
Osamu Nakanishi
P2860
P304
P356
10.1002/IJC.28193
P577
2013-05-06T00:00:00Z